Nuveen LLC Takes Position in 10x Genomics $TXG

Key Points

• Nuveen LLC has acquired a new position in 10x Genomics, purchasing approximately 201,061 shares valued at around <$1.76 million, representing 0.16% ownership.
• Multiple institutional investors, including Invesco Ltd. and Charles Schwab, have increased their holdings in 10x Genomics during the first quarter, highlighting growing interest in the company.
• Despite positive quarterly earnings reports, analysts have mixed views with target price adjustments ranging from $12.00 to $18.00, resulting in an average rating of "Hold" with a price target of $13.54.

Nuveen LLC purchased a new position in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 201,061 shares of the company's stock, valued at approximately $1,755,000. Nuveen LLC owned approximately 0.16% of 10x Genomics at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC increased its holdings in shares of 10x Genomics by 7.5% in the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock valued at $112,143,000 after purchasing an additional 901,656 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of 10x Genomics by 1.7% in the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock valued at $97,061,000 after purchasing an additional 184,537 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock valued at $30,394,000 after purchasing an additional 193,588 shares during the last quarter. Voloridge Investment Management LLC grew its position in 10x Genomics by 12.1% in the fourth quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock worth $22,774,000 after acquiring an additional 171,161 shares during the period. Finally, Two Sigma Investments LP grew its position in 10x Genomics by 291.2% in the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock worth $18,948,000 after acquiring an additional 982,203 shares during the period. Hedge funds and other institutional investors own 84.68% of the company's stock.

Insider Buying and Selling

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the transaction, the chief financial officer directly owned 309,273 shares of the company's stock, valued at $4,264,874.67. This represents a 6.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock valued at $539,865. Company insiders own 9.39% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. lowered their price objective on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Stephens restated an "overweight" rating and set a $14.00 price target on shares of 10x Genomics in a research report on Thursday, May 15th. Finally, Barclays reiterated an "overweight" rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and an average price target of $13.54.

10x Genomics Stock Up 1.7%

TXG stock traded up $0.23 during trading on Thursday, hitting $13.57. The company had a trading volume of 1,709,156 shares, compared to its average volume of 2,840,047. The firm has a market cap of $1.69 billion, a PE ratio of -19.39 and a beta of 2.00. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.38. The firm has a 50-day moving average price of $13.10 and a 200-day moving average price of $10.74.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the previous year, the company earned ($0.32) EPS. The company's quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.